#Epclusa

With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

Additionally, in a recent study, having hep C mutations associated with resistance didn’t affect the outcome of treatment.

A study in Glasgow provided treatment to those receiving opioid substitution therapy for opioid addiction.

Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.

The U.S. FDA released November 13, 2017 new updates on Hepatitis C treatment medications.

Among a large group treated with minimal or no liver fibrosis, liver-health problems were almost nonexistent up to three years later.

Those with stage 3 CKD saw their kidney function improve after treatment with various combo regimens, including Harvoni.

The World Health Organization (WHO) has added a new hepatitis C treatment to its updated 2017 Essential Medicines List.

Epclusa! Now available via our great Australian health care system

A promising new regimen that will address unmet needs for this population is poised for FDA approval.

The triple-drug regimen comes in a once-daily single tablet.

Sorting out the prescribing information regarding hepatitis C treatment and taking acid reflux medications.

The fixed-dose combination tablet sofosbuvir/velpatasvir/voxilaprevir provides a good alternative to those who have failed treatment.

The antiviral drug, which for some people can be a beneficial adjunct to the new crop of hep C medications, has gotten a bad rap.